Literature DB >> 11032888

Evidence for a G protein-coupled gamma-hydroxybutyric acid receptor.

O C Snead1.   

Abstract

gamma-Hydroxybutyric acid (GHB) is a naturally occurring metabolite of GABA that has been postulated to exert ubiquitous neuropharmacological effects through GABA(B) receptor (GABA(B)R)-mediated mechanisms. The alternative hypothesis that GHB acts via a GHB-specific, G protein-coupled presynaptic receptor that is different from the GABA(B)R was tested. The effect of GHB on regional and subcellular brain adenylyl cyclase in adult and developing rats was determined and compared with that of the GABA(B)R agonist (-)-baclofen. Also, using guanosine 5'-O:-(3-[(35)S]thiotriphosphate) ([(35)S]GTPgammaS) binding and low-K:(m) GTPase activity as markers the effects of GHB and (-)-baclofen on G protein activity in the brain were determined. Neither GHB nor baclofen had an effect on basal cyclic AMP (cAMP) levels. GHB significantly decreased forskolin-stimulated cAMP levels by 40-50% in cortex and hippocampus but not thalamus or cerebellum, whereas (-)-baclofen had an effect throughout the brain. The effect of GHB on adenylyl cyclase was observed in presynaptic and not postsynaptic subcellular tissue preparations, but the effect of baclofen was observed in both subcellular preparations. The GHB-induced alteration in forskolin-induced cAMP formation was blocked by a specific GHB antagonist but not a specific GABA(B)R antagonist. The (-)-baclofen-induced alteration in forskolin-induced cAMP formation was blocked by a specific GABA(B)R antagonist but not a specific GHB antagonist. The negative coupling of GHB to adenylyl cyclase appeared at postnatal day 21, a developmental time point that is concordant with the developmental appearance of [(3)H]GHB binding in cerebral cortex, but the effects of (-)-baclofen were present by postnatal day 14. GHB and baclofen both stimulated [(35)S]GTPgammaS binding and low-K:(m) GTPase activity by 40-50%. The GHB-induced effect was blocked by GHB antagonists but not by GABA(B)R antagonists and was seen only in cortex and hippocampus. The (-)-baclofen-induced effect was blocked by GABA(B)R antagonists but not by GHB antagonists and was observed throughout the brain. These data support the hypothesis that GHB induces a G protein-mediated decrease in adenylyl cyclase via a GHB-specific G protein-coupled presynaptic receptor that is different from the GABA(B)R.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032888     DOI: 10.1046/j.1471-4159.2000.0751986.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  17 in total

Review 1.  Succinic semialdehyde dehydrogenase: biochemical-molecular-clinical disease mechanisms, redox regulation, and functional significance.

Authors:  Kyung-Jin Kim; Phillip L Pearl; Kimmo Jensen; O Carter Snead; Patrizia Malaspina; Cornelis Jakobs; K Michael Gibson
Journal:  Antioxid Redox Signal       Date:  2011-04-10       Impact factor: 8.401

Review 2.  Thirty years beyond discovery--clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Authors:  Kara R Vogel; Phillip L Pearl; William H Theodore; Robert C McCarter; Cornelis Jakobs; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2012-06-28       Impact factor: 4.982

Review 3.  Pharmacological and biochemical aspects of GABAergic neurotransmission: pathological and neuropsychobiological relationships.

Authors:  Renê Oliveira Beleboni; Ruither Oliveira Gomes Carolino; Andrea Baldocchi Pizzo; Lissandra Castellan-Baldan; Joaquim Coutinho-Netto; Wagner Ferreira dos Santos; Norberto Cysne Coimbra
Journal:  Cell Mol Neurobiol       Date:  2004-12       Impact factor: 5.046

4.  Neuronal oscillations and synchronicity associated with gamma-hydroxybutyrate during resting-state in healthy male volunteers.

Authors:  Robin von Rotz; Michael Kometer; Dario Dornbierer; Jürg Gertsch; M Salomé Gachet; Franz X Vollenweider; Erich Seifritz; Oliver G Bosch; Boris B Quednow
Journal:  Psychopharmacology (Berl)       Date:  2017-04-20       Impact factor: 4.530

Review 5.  gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness.

Authors:  Daniel Pardi; Jed Black
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

6.  Effects of GABA agonists on body temperature regulation in GABA(B(1))-/- mice.

Authors:  Christophe Quéva; Marianne Bremner-Danielsen; Anders Edlund; A Jonas Ekstrand; Susanne Elg; Sven Erickson; Thore Johansson; Anders Lehmann; Jan P Mattsson
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

7.  Gamma-Hydroxybutyrate Increases Resting-State Limbic Perfusion and Body and Emotion Awareness in Humans.

Authors:  Oliver G Bosch; Fabrizio Esposito; Michael M Havranek; Dario Dornbierer; Robin von Rotz; Philipp Staempfli; Boris B Quednow; Erich Seifritz
Journal:  Neuropsychopharmacology       Date:  2017-05-31       Impact factor: 7.853

8.  Pharmacokinetics and pharmacodynamics of γ-hydroxybutyrate in healthy subjects.

Authors:  Matthias E Liechti; Boris B Quednow; Evangelia Liakoni; Dario Dornbierer; Robin von Rotz; Maria Salomé Gachet; Jürg Gertsch; Erich Seifritz; Oliver G Bosch
Journal:  Br J Clin Pharmacol       Date:  2016-02-25       Impact factor: 4.335

Review 9.  Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid.

Authors:  Marilyn E Morris; Melanie A Felmlee
Journal:  AAPS J       Date:  2008-06-04       Impact factor: 4.009

10.  Circadian distribution of generalized tonic-clonic seizures associated with murine succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Authors:  Lee S Stewart; Kirk J Nylen; Michael A Persinger; Miguel A Cortez; K Michael Gibson; O Carter Snead
Journal:  Epilepsy Behav       Date:  2008-06-02       Impact factor: 2.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.